TP53 mutations and MLH1 mutations appeared in papillary serous adenocarcinoma, and otherwise KRAS mutations and CDKN2A mutations showed up mainly in mucinous adenocarcinoma (Table 3). Here, CDKN2A is linked to papillary serous cystadenocarcinoma.